Full Press Release Details
SAN FRANCISCO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug (“erso”).
The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism (“HI”).
The news, analyst moves, and severe market reaction have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Rezolute may have previously misled investors about erso’s efficacy and commercial prospects.
The firm urges investors in Rezolute who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.
Click here to view Hagens Berman’s video summarizing Hagens Berman’s investigation.
| Contact the Firm Now: | RZLT@hbsslaw.com |
| 844-916-0895 |
Rezolute, Inc. (RZLT) Investigation:
As recently as mid-November, Rezolute assured investors that “in both the real-world setting as well as in clinical studies, erso has shown the potential to substantially eradicate hypoglycemia and improve the quality of life for individuals living with hyperinsulinism[]” and that the Phase 3 study “is poised to be able to rigorously demonstrate the efficacy and safety of ersodetug[.]”
The company also said that an “incredible market opportunity […] lies before us[]” and that after validating the current market assumptions it has “an even greater market opportunity than initially expected[.]”
Investor disappointment abruptly set in on December 11, 2025. That day, Rezolute shocked them when the company announced results of the Phase 3 trial that appeared to contrast with previous assurances. The company said the study did not meet its primary endpoint and the reduction in hypoglycemia events was not statistically significant when compared to placebo. In addition, erso did not meet its secondary endpoint (which assessed change in average daily percent time in hypoglycemia by continuous glucose monitoring) when compared to placebo.
The markets swiftly reacted, sending the price of Rezolute shares crashing as much as 90% that day. Analysts also swiftly reacted, with one reportedly slashing Rezolute’s rating from outperform to neutral and the price target from $12 to $1.
“We’re focused on the degree to which Rezolute may have misled investors about erso’s true efficacy and commercial prospects,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
If you invested in Rezolute and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »
If you’d like more information and answers to frequently asked questions about the Rezolute investigation, read more »
Whistleblowers: Persons with non-public information regarding Rezolute should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email RZLT@hbsslaw.com.
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Reed Kathrein, 844-916-0895